Arcutis Biotherapeutics Inc (NASDAQ: ARQT) on Friday, soared 3.82% from the previous trading day, before settling in for the closing price of $12.31. Within the past 52 weeks, ARQT’s price has moved between $6.88 and $16.20.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 379.27% annually for the last half of the decade. The company achieved an average annual earnings per share of 65.01%. With a float of $102.99 million, this company’s outstanding shares have now reached $117.00 million.
In an organization with 296 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 89.43%, operating margin of -131.16%, and the pretax margin is -140.72%.
Arcutis Biotherapeutics Inc (ARQT) Insider and Institutional Ownership
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Arcutis Biotherapeutics Inc is 11.99%, while institutional ownership is 103.12%. The most recent insider transaction that took place on Feb 03 ’25, was worth 105,893. In this transaction an insider of this company sold 8,338 shares at a rate of $12.70, taking the stock ownership to the 178,692 shares. Before that another transaction happened on Feb 03 ’25, when Company’s insider sold 19,301 for $12.70, making the entire transaction worth $245,123. This insider now owns 804,129 shares in total.
Arcutis Biotherapeutics Inc (ARQT) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.28 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 65.01% per share during the next fiscal year.
Arcutis Biotherapeutics Inc (NASDAQ: ARQT) Trading Performance Indicators
Arcutis Biotherapeutics Inc (ARQT) is currently performing well based on its current performance indicators. A quick ratio of 2.38 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 10.78.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.79, a number that is poised to hit -0.26 in the next quarter and is forecasted to reach -0.83 in one year’s time.
Technical Analysis of Arcutis Biotherapeutics Inc (ARQT)
Let’s dig in a bit further. During the last 5-days, its volume was 3.63 million. That was better than the volume of 2.2 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 59.52%. Additionally, its Average True Range was 1.04.
During the past 100 days, Arcutis Biotherapeutics Inc’s (ARQT) raw stochastic average was set at 58.14%, which indicates a significant increase from 47.97% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 84.96% in the past 14 days, which was higher than the 70.07% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $13.49, while its 200-day Moving Average is $10.47. However, in the short run, Arcutis Biotherapeutics Inc’s stock first resistance to watch stands at $13.00. Second resistance stands at $13.23. The third major resistance level sits at $13.63. If the price goes on to break the first support level at $12.37, it is likely to go to the next support level at $11.97. The third support level lies at $11.74 if the price breaches the second support level.
Arcutis Biotherapeutics Inc (NASDAQ: ARQT) Key Stats
Market capitalization of the company is 1.50 billion based on 117,045K outstanding shares. Right now, sales total 59,610 K and income totals -262,140 K. The company made 44,760 K in profit during its latest quarter, and -41,540 K in sales during its previous quarter.
